08/09/2026
🚨 Pluvicto’s reach has expanded.
And with it, the impact of a Purdue invention becomes even greater.
The FDA has expanded approval of Pluvicto® to PSMA-positive metastatic hormone-sensitive prostate cancer, nearly doubling the eligible patient population. The therapy was invented through research led by Purdue scientist and cancer institute member Philip Low, whose scientific legacy continues to change the treatment landscape for prostate cancer patients.
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach 296 million people worldwide.